본문으로 건너뛰기
← 뒤로

Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma.

1/5 보강
Journal of cancer research and therapeutics 📖 저널 OA 7.4% 2022: 0/3 OA 2023: 1/4 OA 2024: 1/11 OA 2025: 0/21 OA 2026: 2/12 OA 2022~2026 2026 Vol.22(1) p. 178-180 OA
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: lymphoma are poor
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.

Chakravorty A, Purohit BN, Mittal A, Mohan V, Naithani R

📝 환자 설명용 한 줄

The outcomes of elderly patients with lymphoma are poor.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Chakravorty A, Purohit BN, et al. (2026). Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma.. Journal of cancer research and therapeutics, 22(1), 178-180. https://doi.org/10.4103/jcrt.jcrt_1681_25
MLA Chakravorty A, et al.. "Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma.." Journal of cancer research and therapeutics, vol. 22, no. 1, 2026, pp. 178-180.
PMID 41910304 ↗

Abstract

The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1-6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기